Abstract
Peptides with the RGD amino acid sequence show affinity for the alpha(v)beta(3) integrin, an integrin which is over-expressed on angiogenic endothelium and involved in cell adhesion. A peptide with the sequence ATWLPPR has been demonstrated to show affinity for the vascular endothelial growth factor (VEGF) receptor, a receptor involved in the proliferation of endothelial cells. By coupling these peptides to liposomes, these liposomes can serve as a site-specific drug delivery system to tumor endothelial cells in order to inhibit angiogenesis. In the present study we demonstrate that the coupling of cyclic RGD-peptides or ATWLPPR-peptides to the surface of PEG-liposomes results in binding of these liposomes to endothelial cells in vitro. Subsequent studies with RGD-peptide targeted liposomes in vivo also demonstrate specific binding to the tumor endothelium. © 2002 Elsevier Science B.V. All rights reserved.
Original language | English |
---|---|
Pages (from-to) | 55-58 |
Number of pages | 4 |
Journal | International Journal of Pharmaceutics |
Volume | 254 |
Issue number | 1 |
DOIs | |
Publication status | Published - 18 Mar 2003 |
Keywords
- Angiogenesis
- Endothelial cells
- Liposomes
- RGD-peptides
- alanylthreonyltryptophylleucylprolylprolylarginine
- angiogenesis inhibitor
- arginylalanylaspartic acid
- arginylglycylaspartic acid
- liposome
- macrogol
- polypeptide
- unclassified drug
- angiogenesis
- animal experiment
- animal model
- conference paper
- confocal laser scanning microscopy
- controlled study
- drug binding
- drug delivery system
- drug synthesis
- drug targeting
- endothelium
- endothelium cell
- fluorescence activated cell sorting
- human
- human cell
- in vitro study
- in vivo study
- Lewis carcinoma
- mouse
- nonhuman
- priority journal
- neoplasm
- tumor vascularization